Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes.

Published on Dec 1, 2014in Anesthesiology7.067
· DOI :10.1097/ALN.0000000000000472
Ayumi Maeda6
Estimated H-index: 6
(CDC: Centers for Disease Control and Prevention),
Brian T. Bateman65
Estimated H-index: 65
(Harvard University)
+ 2 AuthorsLisa Leffert27
Estimated H-index: 27
(Harvard University)
Sources
Abstract
BACKGROUND: The authors investigated nationwide trends in opioid abuse or dependence during pregnancy and assessed the impact on maternal and obstetrical outcomes in the United States. METHODS: Hospitalizations for delivery were extracted from the Nationwide Inpatient Sample from 1998 to 2011. Temporal trends were assessed and logistic regression was used to examine the associations between maternal opioid abuse or dependence and obstetrical outcomes adjusting for relevant confounders. RESULTS: The prevalence of opioid abuse or dependence during pregnancy increased from 0.17% (1998) to 0.39% (2011) for an increase of 127%. Deliveries associated with maternal opioid abuse or dependence compared with those without opioid abuse or dependence were associated with an increased odds of maternal death during hospitalization (adjusted odds ratio [aOR], 4.6; 95% CI, 1.8 to 12.1, crude incidence 0.03 vs. 0.006%), cardiac arrest (aOR, 3.6; 95% CI, 1.4 to 9.1; 0.04 vs. 0.01%), intrauterine growth restriction (aOR, 2.7; 95% CI, 2.4 to 2.9; 6.8 vs. 2.1%), placental abruption (aOR, 2.4; 95% CI, 2.1 to 2.6; 3.8 vs. 1.1%), length of stay more than 7 days (aOR, 2.2; 95% CI, 2.0 to 2.5; 3.0 vs. 1.2%), preterm labor (aOR, 2.1; 95% CI, 2.0 to 2.3; 17.3 vs. 7.4%), oligohydramnios (aOR, 1.7; 95% CI, 1.6 to 1.9; 4.5 vs. 2.8%), transfusion (aOR, 1.7; 95% CI, 1.5 to 1.9; 2.0 vs. 1.0%), stillbirth (aOR, 1.5; 95% CI, 1.3 to 1.8; 1.2 vs. 0.6%), premature rupture of membranes (aOR, 1.4; 95% CI, 1.3 to 1.6; 5.7 vs. 3.8%), and cesarean delivery (aOR, 1.2; 95% CI, 1.1 to 1.3; 36.3 vs. 33.1%). CONCLUSIONS: Opioid abuse or dependence during pregnancy is associated with considerable obstetrical morbidity and mortality, and its prevalence is dramatically increasing in the United States. Identifying preventive strategies and therapeutic interventions in pregnant women who abuse drugs are important priorities for clinicians and scientists.
📖 Papers frequently viewed together
201245.54JAMA
665 Citations
197 Citations
582 Citations
References43
Newest
#1Brian T. Bateman (Harvard University)H-Index: 65
Last. Krista F. HuybrechtsH-Index: 53
view all 7 authors...
Background There are few data regarding the utilization of opioids during pregnancy. The objective of this study was to define the prevalence and patterns of opioid use in a large cohort of pregnant women who were commercial insurance beneficiaries.
117 CitationsSource
#1Jessica R. Beatty (WSU: Wayne State University)H-Index: 8
#2Sara K. Chase (WSU: Wayne State University)H-Index: 5
Last. Steven J. Ondersma (WSU: Wayne State University)H-Index: 26
view all 3 authors...
Abstract Background Under-reporting of substance use and other sensitive information is a substantial threat to internal study validity, particularly during the perinatal period. Anonymous approaches are associated with greater disclosure but are incompatible with longitudinal follow-up. Alternative approaches include use of a U.S. Federal Certificate of Confidentiality (CoC) and quasi-anonymous methods, in which there is no link between name and data. However, the relative effect of these proce...
15 CitationsSource
#1Victoria Buckley (USYD: University of Sydney)H-Index: 1
#2Abdalvahed RazaghiH-Index: 1
Last. Paul S. Haber (USYD: University of Sydney)H-Index: 52
view all 3 authors...
Background and aims Although methadone maintenance therapy is the standard of care for opioid-dependent pregnant women, there exists controversy over the benefits and side effects of treatment to the neonate. Our aim was to document predictors of neonatal outcomes within an opioid-using population, with particular reference to methadone treatment in the context of continued heroin use. Methods Analysis was performed on a cohort of 183 opioid-using pregnant women seen by the Sydney South West Are...
13 CitationsSource
#1Robert D. StewartH-Index: 8
#2David B. NelsonH-Index: 22
Last. Jeanne S. Sheffield (UTSW: University of Texas Southwestern Medical Center)H-Index: 43
view all 7 authors...
Objective The purpose of this study was to analyze the obstetric and neonatal impact of an opioid detoxification program during pregnancy, as well as to examine variables associated with successful opioid detoxification. Study Design This is a retrospective cohort study of women electing inpatient detoxification and subsequently delivering at our hospital from Jan. 1, 2006, through Dec. 31, 2011. Detoxification was considered successful if women had no illicit drug supplementation at the time of...
53 CitationsSource
111k CitationsSource
#1W. Stromer (University of Graz)H-Index: 2
#1Waltraud Stromer (University of Graz)H-Index: 2
Last. Andreas Sandner-KieslingH-Index: 16
view all 3 authors...
Opioid addiction represents an exaggerated organic and psychological comorbidity and should be regarded as a high-risk problem. Particular features seen perioperatively are tolerance, hyperalgesia and higher analgesic requirement together with physical and psychological withdrawal symptoms. Adequate
38 CitationsSource
128 CitationsSource
#1Jane C. Ballantyne (UW: University of Washington)H-Index: 34
#2Mark D. Sullivan (UW: University of Washington)H-Index: 92
Last. Andrew Kolodny (Maimonides Medical Center)H-Index: 3
view all 3 authors...
51 CitationsSource
#1Stephen W. Patrick (UM: University of Michigan)H-Index: 29
Last. Matthew M. DavisH-Index: 69
view all 6 authors...
Context Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome primarily caused by maternal opiate use. No national estimates are available for the incidence of maternal opiate use at the time of delivery or NAS. Objectives To determine the national incidence of NAS and antepartum maternal opiate use and to characterize trends in national health care expenditures associated with NAS between 2000 and 2009. Design, Setting, and Patients A retrospective, serial, cross-sectional ...
665 CitationsSource
#1Andreea A. CreangaH-Index: 35
#1Andreea A. CreangaH-Index: 23
Last. Leonard J. Paulozzi (CDC: Centers for Disease Control and Prevention)H-Index: 54
view all 9 authors...
OBJECTIVE:To estimate the effect of maternal illicit and prescription drug use on neonates in Washington State between 2000 and 2008.METHODS:We used state-linked birth certificate and hospital discharge (mother and neonate) data to calculate prenatal drug exposure and neonatal abstinence syndrome ra
54 CitationsSource
Cited By146
Newest
#1Evelyn Bae (NewYork–Presbyterian Hospital)H-Index: 1
#2Virginia Tangel (Cornell University)H-Index: 8
Last. Robert S. White (NewYork–Presbyterian Hospital)H-Index: 14
view all 5 authors...
AbstractObjective: We compared post-partum outcomes between sickle cell disease (SCD) and non-sickle cell populations.Methods: We conducted a retrospective analysis of discharge data for 6,911,916 ...
1 CitationsSource
#1Jessica M. Barry (UMN: University of Minnesota)H-Index: 1
#2Angela K. Birnbaum (UMN: University of Minnesota)H-Index: 24
Last. Catherine M.T. Sherwin (Wright State University)H-Index: 30
view all 0 authors...
The public health crisis of pregnant women being exposed to drugs of abuse and of its impact on their unborn children continues to grow at an alarming rate globally. The state of pregnancy is unique, with physiological changes that can lead to changes in the way drugs are handled by the body in both pharmacokinetics and response. These changes place the pregnant woman, fetus, and newborn infant at risk, as many of these drugs can cross the placenta and into breast milk. The substances most commo...
1 CitationsSource
#1Danielle N. Atkins (UCF: University of Central Florida)H-Index: 5
#2Christine Piette Durrance (UW: University of Wisconsin-Madison)
view all 2 authors...
Abstract null null Background null The U.S. is facing a substance use crisis. One consequence, resulting from overdose deaths, arrests, parental and prenatal substance use, is increased reliance on the foster care system. In response to concerns about prenatal substance use, some states adopted policies that treat prenatal substance use identified at birth as child abuse or neglect. null null null Objective null To investigate the effects of state-level policies treating prenatal substance use a...
Source
#1Nicola C. Perlman (Brigham and Women's Hospital)H-Index: 3
#2David E. Cantonwine (Brigham and Women's Hospital)H-Index: 29
Last. Nicole A. Smith (Brigham and Women's Hospital)H-Index: 15
view all 3 authors...
OBJECTIVE null A rising incidence in maternal drug use during pregnancy has led to a concomitant rise in neonatal opioid withdrawal syndrome. Despite evidence that drug use during pregnancy affects all demographic groups equally, authors of recent studies have suggested that minority women are tested for drug use more than their counterparts. In this study, we aimed to assess whether toxicology testing of neonates was associated with maternal characteristics. null METHODS null Retrospective coho...
Source
#1Stephanie Anne Deutsch (Alfred I. duPont Hospital for Children)H-Index: 1
#2Jennifer Donahue (Wilmington University)
Last. Allan De Jong (Alfred I. duPont Hospital for Children)H-Index: 1
view all 5 authors...
Abstract null null Improving health and well-being of mothers, infants, and children represents a national public health priority, with emphasis placed on understanding how environmental and social determinants (access to quality health care, education, employment, economic opportunities, social support, and resource availability) influence maternal health behaviors and infant-child well-being. Substance use during pregnancy is a predominant maternal-infant health risk; many affected mother-infa...
Source
ABSTRACT New clinical studies indicate that buprenorphine can be a promising alternative to methadone for treating opioid use disorder (OUD) in pregnant women. Various benefits for the mother have been identified with buprenorphine's unique pharmacokinetics, effect on clinical outcomes, and convenience for the patient. With the growing problem of OUD in pregnant women, clinicians must be aware of treatment options and their associated advantages and disadvantages.
Source
#1Erin M. Cleary (OSU: Ohio State University)H-Index: 1
#2Marcela C. Smid (UofU: University of Utah)H-Index: 13
Last. Kara M. Rood (OSU: Ohio State University)H-Index: 9
view all 7 authors...
Buprenorphine is one of three medications approved by the US Food and Drug administration for treatment of opioid use disorder, and practitioners must obtain a federal waiver in order to prescribe buprenorphine. Until recently, physicians and advanced practice clinicians were required to complete 8 and 24 hours of training, respectively, before applying for this waiver and to provide psychosocial services when prescribing buprenorphine to 30 or fewer patients. The US Department of Health and Hum...
Source
#1Vickie Harden (MT: Middle Tennessee State University)
#2Isabela Romas (MT: Middle Tennessee State University)
Last. Marva L. Lewis (Tulane University)H-Index: 8
view all 4 authors...
The opioid epidemic has left pregnant and post-partum women in serious need of a specialized approach to ensure effective treatment interventions. It is challenging to provide services that effecti...
Source
#1Henriikka Hakomäki (University of Eastern Finland)H-Index: 1
#2Hannu Kokki (University of Eastern Finland)H-Index: 37
Last. Merja KokkiH-Index: 15
view all 7 authors...
Abstract null null Background null Buprenorphine is used in the opioid maintenance treatment for opioid dependent patients, including pregnant women. Despite the wide use, limited data exists on buprenorphine pharmacokinetics and fetal exposure during pregnancy. The aim of our study was to determine the buprenorphine pharmacokinetics during transdermal patch dosing to pregnant sheep and, to determine the extent of transplacental transfer of buprenorphine to the fetus. null null null Methods null...
Source
#1Rebecca R S Clark (UPenn: University of Pennsylvania)H-Index: 1
#2Rachel French (UPenn: University of Pennsylvania)H-Index: 3
Last. Eileen T. Lake (UPenn: University of Pennsylvania)H-Index: 32
view all 6 authors...
BACKGROUND AND OBJECTIVES We measured within-hospital concordance of mothers with opioid use disorder (OUD) and newborns with neonatal abstinence syndrome (NAS) or opioid exposure (OE). Secondarily, we described the demographics of mothers and newborns with and without opioid-related diagnoses. METHODS We used hospital discharge abstracts from California, Florida, New Jersey, and Pennsylvania in 2016. Descriptive statistics were used to compare newborns and mothers with and without opioid-relate...
Source